HOME >> MEDICINE >> NEWS
Hopkins study proves cochlear implants prevent or reverse damage to brain's auditory nerve system

ansmitter chemicals necessary to pass sound signals between nerve cells; and the specialized nerve membranes that receive the signal were small and dome-shaped. In the deaf cats without implants, synaptic vesicles were absent, and the specialized nerve membranes were large and flat.

Niparko, who has for more than 20 years been studying the effects of hearing restoration in children, says the next research goal is to determine what happens between birth and puberty in the auditory system to diminish the chances of restoring hearing and language skills over time. Future experiments will evaluate brain changes that occur when an animal grows up in an environment that is devoid of sound, which the scientists believe will guide future therapies in restoring useful hearing to the deaf.


'"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
1-Dec-2005


Page: 1 2 3

Related medicine news :

1. Johns Hopkins begins aggressive screening for superbugs in children
2. Johns Hopkins develops pancreas cancer risk model
3. Hopkins study reveals white blood cells can both hurt and help transplanted kidneys
4. Hopkins scientists link immune response to ghost parasites and severely congested sinuses
5. Hopkins-led study finds that chronic form of depression runs in families
6. Diagnosis and referrals for kidney disease fall well short of need, Johns Hopkins study shows
7. Johns Hopkins Childrens Center to lead largest-ever study on kidney disease in children
8. Hopkins scientists show hallucinogen in mushrooms creates universal mystical experience
9. Johns Hopkins lab scientists tame overactive CF protein
10. Hopkins researchers develop new quick tool to sort out insect bites in children
11. Hopkins scientists use embryonic stem cells, new cues to awaken latent motor nerve repair

Post Your Comments:
(Date:5/18/2013)... (PRWEB) May 18, 2013 Adolescents, especially ... known as “Spice” or “K2” are landing in emergency ... to curb this drug epidemic with a new ... marijuana. , According to research from the National Institute ... popular illegal drug among American teenagers. In 2012, 11 ...
(Date:5/18/2013)... DF (PRWEB) May 18, 2013 The ... leading ayurvedic education institution in the West. Program is ... education. , Ayurveda is a healing modality practiced for ... ), it is considered that health begins when an ... profound understanding of their individual needs. Ayurveda aims to ...
(Date:5/18/2013)... Bay, CA (PRWEB) May 18, 2013 ... , has recently completed a stylish renovation that features ... advanced specialties. , From the ground up, this ... improved with fresh flooring, soothing colors and comfortable spa ... been installed, including an Apilus epilator machine. The ...
(Date:5/18/2013)... 2013 Losing weight remains to be the ... horde of new weight loss products available in the market ... studies about this newest weight loss supplement prove that dieting ... , Garcinia Cambogia is a sub-tropical fruit that is shaped ... fruit can suppress a person’s appetite, while it effectively burns ...
(Date:5/18/2013)... Spectrum Surgical Instruments will attend ... in Austin, TX where thousands of GI nursing ... opportunities. , Spectrum Surgical/STERIS will feature its ... capabilities and certified pre-owned equipment. Attendees will ... proper instrument care of flexible endoscopes. , ...
Breaking Medicine News(10 mins):Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... May 17, 2013  Boehringer Ingelheim will contribute ... at the American Thoracic Society International Conference (ATS ... May 17 – 22. Data will ... the treatment of chronic obstructive pulmonary disease (COPD) ... as investigational compounds for asthma, idiopathic pulmonary fibrosis ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
Cached News: